Dow Jones
39.169,52 +50,66 (+0,13%) Nasdaq
17.879,30 +146,70 (+0,83%) Nikkei 225
39.631,06 +47,98 (+0,12%) EUR/USD
1,0740 -0,0002 (-0,02%) Bitcoin EUR
58.601,89 +151,65 (+0,26%) CMC Crypto 200
1.344,27 +42,20 (+3,24%)
CLSD Jul 2024 2.500 put
| Chiusura precedente | 1,2500 |
| Aperto | 1,2500 |
| Denaro | 1,0000 |
| Domanda | 1,5000 |
| Prezzo d'esercizio | 2,50 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 1,2500 - 1,2500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 48 |
GlobeNewswireClearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 - ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial wer
- GlobeNewswire
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that Arctic Vision, Clearside’s partner, has successfully completed enrollment in its Phase 3 randomized, double-blind, placebo-controlled clinical tri
- GlobeNewswire
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Charles A. Deignan, Chief Financial Officer, will participate in a panel discussion at the JonesTrading 2023 Healthcare Summit. The panel, entitled, All About Eyes: Paradigm Shifting Therapeutic Innovations in Ophthalmology will take place on October
